+
Open data
-
Basic information
Entry | ![]() | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Title | Structure of human SLC2A9 transporter | |||||||||
![]() | Sharpen final map after refinement | |||||||||
![]() |
| |||||||||
![]() | Transporter / MEMBRANE PROTEIN | |||||||||
Function / homology | ![]() Defective SLC2A9 causes hypouricemia renal 2 (RHUC2) / fructose transmembrane transporter activity / fructose transmembrane transport / dehydroascorbic acid transport / hexose transmembrane transport / carbohydrate:proton symporter activity / Cellular hexose transport / D-glucose transmembrane transporter activity / D-glucose transmembrane transport / urate transport ...Defective SLC2A9 causes hypouricemia renal 2 (RHUC2) / fructose transmembrane transporter activity / fructose transmembrane transport / dehydroascorbic acid transport / hexose transmembrane transport / carbohydrate:proton symporter activity / Cellular hexose transport / D-glucose transmembrane transporter activity / D-glucose transmembrane transport / urate transport / urate metabolic process / urate transmembrane transporter activity / D-glucose import / transmembrane transporter activity / electron transport chain / basolateral plasma membrane / periplasmic space / electron transfer activity / apical plasma membrane / iron ion binding / heme binding / membrane / plasma membrane Similarity search - Function | |||||||||
Biological species | ![]() ![]() | |||||||||
Method | single particle reconstruction / cryo EM / Resolution: 3.37 Å | |||||||||
![]() | Khandelwal NK / Gupta M / Stroud RM | |||||||||
Funding support | ![]()
| |||||||||
![]() | ![]() Title: Structural basis of disease mutation and substrate recognition by the human SLC2A9 transporter. Authors: Nitesh Kumar Khandelwal / Meghna Gupta / Paras Kumar / Sree Ganesh Balasubramani / Ignacia Echeverria / Robert M Stroud / ![]() Abstract: Urate provides ~50% of the reducing potential in human and primate plasma which is key to detoxifying reactive oxygen by-products of cellular metabolism. Urate is the endpoint of purine metabolism in ...Urate provides ~50% of the reducing potential in human and primate plasma which is key to detoxifying reactive oxygen by-products of cellular metabolism. Urate is the endpoint of purine metabolism in primates, and its concentration in plasma is a balance between excretion from kidney and intestine, and subsequent reabsorption in and through cells of kidney proximal tubules to maintain a regulated concentration in plasma. SLC2A9 is the primary transporter that returns urate from the basolateral side of kidney tubule cells back to plasma. A shorter splice variant of SLC2A9 is directed to the apical surface where several transporters recapture urate from the tubule back into cells. Too high a concentration in plasma causes hyperuricemia, is linked to gout, and favors kidney stone formation. To understand the molecular basis of uric acid transport and the role of disease-causing mutations in SLC2A9, we determined structures of human SLC2A9 in its apo form, and its urate-bound form by cryo-EM, at resolution of 3.3 Å and 4.1 Å respectively. Both structures are captured in an inward open conformation. Using the inward-facing structure as a template we modeled the outward-facing conformation to understand the alternating access mechanism. Alternative salt bridge pairs on the cytoplasmic side suggest a mechanism that can balance the energetics of the inward open and outward open states. The location of disease-causing mutants suggests their role in impacting function. Our structures elucidate the molecular basis for urate selectivity and transport and provide a platform for future structure-based drug discovery aimed at reducing plasma urate levels in diseases of hyperuricemia and gout. | |||||||||
History |
|
-
Structure visualization
Supplemental images |
---|
-
Downloads & links
-EMDB archive
Map data | ![]() | 167.9 MB | ![]() | |
---|---|---|---|---|
Header (meta data) | ![]() ![]() | 25.1 KB 25.1 KB | Display Display | ![]() |
FSC (resolution estimation) | ![]() | 11.9 KB | Display | ![]() |
Images | ![]() | 49.1 KB | ||
Masks | ![]() | 178 MB | ![]() | |
Filedesc metadata | ![]() | 7 KB | ||
Others | ![]() ![]() ![]() | 88.3 MB 165.2 MB 165.2 MB | ||
Archive directory | ![]() ![]() | HTTPS FTP |
-Validation report
Summary document | ![]() | 799.3 KB | Display | ![]() |
---|---|---|---|---|
Full document | ![]() | 798.9 KB | Display | |
Data in XML | ![]() | 20.7 KB | Display | |
Data in CIF | ![]() | 26.9 KB | Display | |
Arichive directory | ![]() ![]() | HTTPS FTP |
-Related structure data
Related structure data | ![]() 9caxMC ![]() 9cbbC M: atomic model generated by this map C: citing same article ( |
---|---|
Similar structure data | Similarity search - Function & homology ![]() |
-
Links
EMDB pages | ![]() ![]() |
---|---|
Related items in Molecule of the Month |
-
Map
File | ![]() | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Sharpen final map after refinement | ||||||||||||||||||||||||||||||||||||
Projections & slices | Image control
Images are generated by Spider. | ||||||||||||||||||||||||||||||||||||
Voxel size | X=Y=Z: 0.8189 Å | ||||||||||||||||||||||||||||||||||||
Density |
| ||||||||||||||||||||||||||||||||||||
Symmetry | Space group: 1 | ||||||||||||||||||||||||||||||||||||
Details | EMDB XML:
|
-Supplemental data
-Mask #1
File | ![]() | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projections & Slices |
| ||||||||||||
Density Histograms |
-Additional map: Unsharpen final map after refinement
File | emd_45406_additional_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Unsharpen final map after refinement | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: Half map A
File | emd_45406_half_map_1.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half map A | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-Half map: Half map B
File | emd_45406_half_map_2.map | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Annotation | Half map B | ||||||||||||
Projections & Slices |
| ||||||||||||
Density Histograms |
-
Sample components
-Entire : Codon optimize SLC2A9 gene was synthesize and cloned in 83 nu yea...
Entire | Name: Codon optimize SLC2A9 gene was synthesize and cloned in 83 nu yeast expressing vector from GenScript. Protein expressed in yeast cells and purified using Ni-affinity followed by Sizing. |
---|---|
Components |
|
-Supramolecule #1: Codon optimize SLC2A9 gene was synthesize and cloned in 83 nu yea...
Supramolecule | Name: Codon optimize SLC2A9 gene was synthesize and cloned in 83 nu yeast expressing vector from GenScript. Protein expressed in yeast cells and purified using Ni-affinity followed by Sizing. type: complex / ID: 1 / Parent: 0 / Macromolecule list: all |
---|---|
Source (natural) | Organism: ![]() |
Molecular weight | Theoretical: 69.78906 KDa |
-Macromolecule #1: Soluble cytochrome b562,Solute carrier family 2, facilitated gluc...
Macromolecule | Name: Soluble cytochrome b562,Solute carrier family 2, facilitated glucose transporter member 9 type: protein_or_peptide / ID: 1 Details: N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag ...Details: N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag,N-terminal Flag tag, HRV3C site followed by BRIL tag N-terminal truncated SlC2A9 isoform 1 (residue 52-540 as per uniprot). C terminal thrombin site followed by 10X his tag Number of copies: 1 / Enantiomer: LEVO |
---|---|
Source (natural) | Organism: ![]() |
Molecular weight | Theoretical: 69.859695 KDa |
Recombinant expression | Organism: ![]() ![]() |
Sequence | String: MASDYKDDDD KGALEVLFQG PSSPMADLED NWETLNDNLK VIEKADNAAQ VKDALTKMRA AALDAQKATP PKLEDKSPDS PEMKDFRHG FDILVGQIDD ALKLANEGKV KEAQAAAEQL KTTRNAYIQK YLSCSLLVAS LAGAFGSSFL YGYNLSVVNA P TPYIKAFY ...String: MASDYKDDDD KGALEVLFQG PSSPMADLED NWETLNDNLK VIEKADNAAQ VKDALTKMRA AALDAQKATP PKLEDKSPDS PEMKDFRHG FDILVGQIDD ALKLANEGKV KEAQAAAEQL KTTRNAYIQK YLSCSLLVAS LAGAFGSSFL YGYNLSVVNA P TPYIKAFY NESWERRHGR PIDPDTLTLL WSVTVSIFAI GGLVGTLIVK MIGKVLGRKH TLLANNGFAI SAALLMACSL QA GAFEMLI VGRFIMGIDG GVALSVLPMY LSEISPKEIR GSLGQVTAIF ICIGVFTGQL LGLPELLGKE STWPYLFGVI VVP AVVQLL SLPFLPDSPR YLLLEKHNEA RAVKAFQTFL GKADVSQEVE EVLAESRVQR SIRLVSVLEL LRAPYVRWQV VTVI VTMAC YQLCGLNAIW FYTNSIFGKA GIPPAKIPYV TLSTGGIETL AAVFSGLVIE HLGRRPLLIG GFGLMGLFFG TLTIT LTLQ DHAPWVPYLS IVGILAIIAS FCSGPGGIPF ILTGEFFQQS QRPAAFIIAG TVNWLSNFAV GLLFPFIQKS LDTYCF LVF ATICITGAIY LYFVLPETKN RTYAEISQAF SKRNKAYPPE EKIDSAVTDG KINGRPGLVP RGSSAHHHHH HHHHHGA UniProtKB: Soluble cytochrome b562, Solute carrier family 2, facilitated glucose transporter member 9 |
-Experimental details
-Structure determination
Method | cryo EM |
---|---|
![]() | single particle reconstruction |
Aggregation state | particle |
-
Sample preparation
Concentration | 7 mg/mL | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Buffer | pH: 7.5 Component:
Details: 4 degree cold buffer pH7.5 (300mM NaCl, 50mM Tris and 0.02% GDN) | |||||||||
Grid | Model: Quantifoil R1.2/1.3 / Material: GOLD / Mesh: 400 / Support film - Material: CARBON / Support film - topology: HOLEY / Pretreatment - Type: GLOW DISCHARGE / Pretreatment - Time: 30 sec. / Pretreatment - Pressure: 0.033 kPa / Details: 30 second glow 30 sec hold | |||||||||
Vitrification | Cryogen name: ETHANE / Chamber humidity: 100 % / Chamber temperature: 277.15 K / Instrument: FEI VITROBOT MARK IV |
-
Electron microscopy
Microscope | FEI TITAN KRIOS |
---|---|
Image recording | Film or detector model: GATAN K3 (6k x 4k) / Number grids imaged: 1 / Number real images: 10503 / Average exposure time: 2.0 sec. / Average electron dose: 47.7 e/Å2 |
Electron beam | Acceleration voltage: 300 kV / Electron source: ![]() |
Electron optics | C2 aperture diameter: 70.0 µm / Illumination mode: FLOOD BEAM / Imaging mode: OTHER / Cs: 2.7 mm / Nominal defocus max: 2.0 µm / Nominal defocus min: 1.0 µm |
Sample stage | Cooling holder cryogen: NITROGEN |
Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |